Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-Label Extension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- 26 Jan 2009 Patient number amended from 554 to 559 as reported by ClinicalTrials.gov.
- 26 Oct 2008 Actual patient number (564) added as reported by ClinicalTrials.gov.
- 17 Aug 2008 Actual end date added (Dec 2007) as reported by ClinicalTrials.gov.